<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<key-projects><projects><title>Prescription Drug User Fee Act (PDUFA) Reauthorization</title><description>Activities to support reauthorization of the Prescription Drug User Fee Act (PDUFA) to ensure sound financial support for new drug review.</description><dictionary></dictionary><outcome></outcome><accomplishment></accomplishment><table><title>Prescription Drug User Fee Act (PDUFA) Reauthorization</title><overall-status><briefing>COMPLETED</briefing><prior-briefing>ON TRACK</prior-briefing></overall-status><row><type></type><milestone-description>1. Gather feedback on suggestions regarding reauthorization including specific suggestions for changes to the PDUFA goals, hold a public meeting and open a docket to gather written comments</milestone-description><milestone-date>5/1/2010</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>5/1/2010</milestone-completion-date></row><row><type></type><milestone-description>2. Analyze written comments submitted to the docket to inform stakeholder and industry discussions</milestone-description><milestone-date>6/30/2010</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>6/30/2010</milestone-completion-date></row><row><type></type><milestone-description>3. Meet monthly (starting in June) with representatives of patient and consumer advocacy groups to continue discussions to inform FDA on recommendations for reauthorization</milestone-description><milestone-date>5/31/2011</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>5/31/2011</milestone-completion-date></row><row><type></type><milestone-description>4. Conduct negotiations and reach agreement with the regulated industry on user fee program reauthorization</milestone-description><milestone-date>5/31/2011</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>5/31/2011</milestone-completion-date></row><row><type></type><milestone-description>5. Submit package of proposal recommendations for reauthorization for administration review and clearance</milestone-description><milestone-date>6/1/2011</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>6/1/2011</milestone-completion-date></row><row><type></type><milestone-description>6. To gather feedback on the proposal recommendations for reauthorization , hold a public meeting, and open a docket to gather written comments</milestone-description><milestone-date>11/15/2011</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>11/15/2011</milestone-completion-date></row><row><type></type><milestone-description>7. Analyze written comments submitted to the docket</milestone-description><milestone-date>12/15/2011</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>12/15/2011</milestone-completion-date></row><row><type></type><milestone-description>8. Transmit final package of prepared recommendations for reauthorization to Congress by January 15, 2012</milestone-description><milestone-date>1/15/2012</milestone-date><milestone-status>Completed</milestone-status><milestone-completion-date>1/15/2012</milestone-completion-date></row><footnotes><note></note></footnotes></table></projects><related-links><link><url>http://www.fda.gov/AboutFDA/Transparency/track/ucm206444.htm</url><text>FDA-TRACK CDER Dashboard</text></link></related-links></key-projects>
    






